Becton Dickinson & Co reported fourth-quarter revenue of $5.3 billion, up 5.6%, and adjusted EPS of $4.15, up 27.3%. Guidance calls for low single-digit revenue growth and adjusted EPS of $13.10 to $13.30.
BDX · Becton Dickinson & Co
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
The closing range begins at the captured split on Feb 10, 2026.
Up next
Latest documents
Becton, Dickinson and Company reported FY26 revenue of $19.5 billion, up 4.9%, adjusted diluted EPS of $12.70, and fiscal 2027 adjusted diluted EPS guidance of $13.10 to $13.30.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q4 FY26 earnings call · Nov 5, 2026TL;DR. BD delivered strong FY26 growth, Q4 margin expansion and 42% free-cash-flow growth, while returning $3.6 billion to shareholders. FY27 guidance calls for low single-digit revenue growth, with Alaris and currency headwinds and roughly flat operating margin.
- + Q4 revenue grew 5.6% to $5.3 billion and adjusted EPS grew 27.3% to $4.15.
- + FY26 revenue grew 3.9% to $19.5 billion and adjusted EPS grew 6.7% to $12.70.
- + Q4 adjusted gross margin was 56.8% and adjusted operating margin expanded to 28.6%.
- + FY26 free cash flow increased 42% to $2.9 billion and conversion rose to 74% including separation costs.
- + BD returned $3.6 billion to shareholders in FY26, including approximately $2.4 billion of share repurchases and $1.2 billion in dividends.
- + The Liberty tip stent graft received FDA approval in Q4 and is seeing strong customer interest.
- − FY27 revenue guidance is for low single-digit growth.
- − The Alaris capital comparison creates approximately 200 basis points of pressure in FY27.
- − Currency is expected to be a headwind of about 70 basis points to FY27 revenue growth.
- − FY27 adjusted operating margin is expected to be roughly flat year over year.
- − FY26 adjusted operating margin declined 20 basis points, and tariffs had a 90 basis-point impact.
- − Vaccines declined about 11% in Q4.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Diluted Earnings per Share from Continuing Operations non-GAAP | $8.59 | Nine Months Ended June 30, 2026 | — |
| Free Cash Flow non-GAAP | $1.73B | Nine Months Ended June 30, 2026 | — |
| Net Cash Provided by Continuing Operating Activities | $2.1B | Nine Months Ended June 30, 2026 | — |
| Segment income as % of BioPharma Systems revenues | 38.6% | three months ended June 30, 2026 filing | — |
| Segment income as % of Connected Care revenues | 32.3% | three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BDX
this stock
Becton Dickinson & Co
|
$58.68B | — | +8.2% | 95.3 | 3.0% |
|
ISRG
Intuitive Surgical Inc
|
$149.24B | -24.0% | +20.5% | 52.2 | 2.0% |
|
MDLN
Medline Inc.
|
$49.56B | -10.3% | +11.5% | — | 2.9% |
|
ALC
Alcon Inc
|
$35.60B | -6.0% | +10.5% | — | 3.8% |
|
RMD
Resmed Inc
|
$33.46B | -1.3% | +13.4% | 21.7 | 7.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 23
Becton, Dickinson and Company reported FY26 revenue of $19.5 billion, up 4.9%, adjusted diluted EPS of $12.70, and fiscal 2027 adjusted diluted EPS guidance of $13.10 to $13.30.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BDX | +1.3% | +11.2% | +45.2% | +8.9% | +41.2% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | +3.7% | +15.9% | +48.1% | +11.9% | +33.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.